Rezera announces positive Resolve-2 Phase 2 results for ruvonoflast plus semaglutide
Reuters says Resolve-2 Phase 2 showed the ruvonoflast plus semaglutide combination had greater HSCRP reductions versus semaglutide alone and no new safety signals.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.